ReviewDiabetologia2012
Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.
Review in Diabetologia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies.Journal of endocrinological investigation · 2025Guideline
- Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- The impact of having both cancer and diabetes on patient-reported outcomes: a systematic review and directions for future research.Journal of cancer survivorship : research and practice · 2016Pooled it
- Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.Breast cancer research : BCR · 2015Pooled it
- Diabetes mellitus and colorectal cancer prognosis: a meta-analysis.Diseases of the colon and rectum · 2013Pooled it
- Diabetes and cancer: glucose control impact on survival and tumor outcomes.Reviews in endocrine & metabolic disorders · 2026Review
- Antihypertensive Treatment and Cancer: Umbrella Review of Meta-Analyses of Randomized Controlled Trials and Observational Studies.Research in heart yield and translational medicine · 2026Review
- LEP and FOXO1 genes, as a proposed tumor suppressor autophagic cell death related genes, can be targeted by antidiabetic therapy in nondiabetic breast cancer patients.Discover oncology · 2025Article
- Impact of Perioperative Hemoglobin A1c Levels on Survival Outcomes of Patients With Pancreatic Cancer: A Retrospective Study.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2025Article
- Younger-onset type 2 diabetes associated with increased long-term cancer risk in Chinese adults: A 30-year follow-up of the Da Qing Diabetes Study.BJC reports · 2025Article
- Associations between cardiometabolic comorbidities and mortality in adults with cancer: multinational cohort study.BMJ medicine · 2025Article
- Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view.Journal of endocrinological investigation · 2024Review
- Exploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation.Biomolecules · 2024Article
- Incident Cancer Risk in Patients with Incident Type 2 Diabetes Mellitus in Hungary (Part 1).Cancers · 2024Article
- Impact of diabetes on surgery and radiotherapy for breast cancer.Breast cancer research and treatment · 2023Article
- Equity of Cancer and Diabetes Co-Occurrence: A National Study With 44 Million Person-Years of Follow-Up.JCO global oncology · 2023Article
- Impact of coexisting diabetes on survival and risk of developing second primary cancer in diabetes patients receiving drug therapy: A multicenter retrospective cohort study of patients with cancer in Japan.Journal of diabetes investigation · 2023Article
- Association of dietary sodium intake with impaired fasting glucose in adult cancer survivors: A population-based cross-sectional study.PloS one · 2023Article
- Cancer, diabetes, survival and glycemic control: a large multisite analysis.Future science OA · 2022Article
- Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.Breast cancer research and treatment · 2022Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In this paper we address methodological aspects of aetiological importance in the link between diabetes and mortality in patients with cancer. We identified nine key points on the cancer pathway at which confounding may arise-cancer screening use, stage at diagnosis, cancer treatment selection, cancer treatment complications and failures, peri-treatment mortality, competing risks for long-term mortality, effects of type 2 diabetes on anti-cancer therapies, effects of glucose-lowering treatments on cancer outcome and differences in tumour biology. Two types of mortality studies were identified: (1) inception cohort studies that evaluate the effect of baseline diabetes on cancer-related mortality in general populations, and (2) cohorts of patients with a cancer diagnosis and pre-existing type 2 diabetes. We demonstrate, with multiple examples from the literature, that pre-existing diabetes affects presentation, cancer treatment, and outcome of several common cancer types, often to varying extents. Diabetes is associated with increased all-cause mortality in cancer patients, but the evidence that it influences cancer-specific mortality is inconsistent. In the absence of data that address the potential biases and confounders outlined in the above framework, we caution against the reporting of cancer-related mortality as a main endpoint in analyses determining the impact of diabetes and glucose-lowering medications on risk of cancer.
Indexed as
Identifiers
22476948What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.